Trusted by:

clients clients clients clients clients clients clients clients clients clients
Newswise: Diabetes Drug Appears to Fight Lung Cancer — But Only in Overweight or Obese Patients
Released: 26-Nov-2024 8:00 AM EST
Diabetes Drug Appears to Fight Lung Cancer — But Only in Overweight or Obese Patients
Roswell Park Comprehensive Cancer Center

A widely accessible drug commonly used to control blood glucose levels in diabetic patients has the potential to strengthen the effects of immunotherapy and improve recurrence-free survival in people with lung cancer who are overweight or obese, according to a recently published article in the Journal of the National Cancer Institute.

Newswise: Virtual Replicas for Real-World Solutions: Digital Twins in Action
Released: 26-Nov-2024 7:50 AM EST
Virtual Replicas for Real-World Solutions: Digital Twins in Action
Chinese Academy of Sciences

In a significant advancement for industrial technology, scientists have introduced a revolutionary digital twin (DT) platform designed to transform the process industry. This cutting-edge platform creates a highly accurate virtual replica of physical systems, allowing companies to optimize operations, enhance productivity, and fuel innovation like never before.

Newswise: Beyond Lithium: The Rise of Sustainable Battery Alternatives
Released: 26-Nov-2024 7:35 AM EST
Beyond Lithium: The Rise of Sustainable Battery Alternatives
Chinese Academy of Sciences

Scientists are exploring non-lithium-ion batteries as a sustainable alternative to traditional lithium-ion batteries, focusing on sodium, potassium, magnesium, and calcium-ion technologies. This research is crucial for developing clean energy systems that are both environmentally friendly and rely on abundantly available elements, ensuring a more secure and eco-friendly future for energy storage.

Newswise: Novel Gene Therapy Trial for Sickle Cell Disease Launches
Released: 26-Nov-2024 7:30 AM EST
Novel Gene Therapy Trial for Sickle Cell Disease Launches
University of California, San Francisco (UCSF)

UCSF Benioff Children's Hospital Oakland is enrolling patients in an innovative clinical trial that seeks to cure sickle cell disease. The trial is the first in the U.S. to apply non-viral CRISPR-Cas9 gene-editing technology in humans to directly correct the genetic mutation that causes the disease.

Newswise:Video Embedded behind-the-model-science-inspired-by-legos
VIDEO
Released: 26-Nov-2024 7:00 AM EST
Behind the Model: Science Inspired by Legos
Thomas Jefferson National Accelerator Facility

Walt Akers, Jefferson Lab’s chief systems engineer for experimental nuclear physics, created a 3D-printed model of a section of the Electron-Ion Collider (EIC) on a short timeline ahead of the lab’s 2024 Open House. He calls it the “Lego model.”

23-Nov-2024 11:45 PM EST
Quantifying Disease Impact and Overcoming Practical Treatment Barriers for Primary Progressive Aphasia
University of Chicago Medical Center

Two new papers show progress in researchers' work to illuminate the struggles of those living with PPA and pioneer accessible treatment models.

Newswise: Transplanting Healthy Reef Ecosystems to Damaged Reefs Improves Coral Health
Released: 26-Nov-2024 2:30 AM EST
Transplanting Healthy Reef Ecosystems to Damaged Reefs Improves Coral Health
Bar-Ilan University

A pioneering study has revealed significant improvements in coral health through an innovative approach of transplanting healthy reef ecosystems to damaged reefs. The study offers new hope for coral reef restoration and the fight against widespread coral decline.

Newswise: Technological Breakthrough in Carbon Nanotube Applications for Battery Dry Process
Released: 26-Nov-2024 12:00 AM EST
Technological Breakthrough in Carbon Nanotube Applications for Battery Dry Process
National Research Council of Science and Technology

Dr. Joong Tark Han‘s team at KERI produced the world’s first powdered, highly dispersible CNT conductive additive. Successful dispersion of CNTs with a strong tendency to agglomerate – opening up avenues for high-capacity secondary battery applications.

Not for public release

This news release is embargoed until 25-Nov-2024 5:00 PM EST Released to reporters: 19-Nov-2024 2:00 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 25-Nov-2024 5:00 PM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Not for public release

This news release is embargoed until 25-Nov-2024 5:00 PM EST Released to reporters: 19-Nov-2024 2:00 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 25-Nov-2024 5:00 PM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.


close
1.66609